SOPHiA DDM™ Dx Solid Tumor Solution

High-performance profiling to optimize solid tumor management

Accurate detection and reporting of clinically relevant biomarkers are critical for better patient management.

SOPHiA DDM™ Dx Solid Tumor Solution (STS) is a CE-marked in vitro diagnostic (IVD) application based on next-generation sequencing (NGS) enabling accurate and sensitive characterization of the complex mutational landscape associated with major solid tumors. Powered by the advanced analytical capabilities of SOPHiA DDM™ Platform, this sample-to-report application helps healthcare professionals increase their efficiency and confidence of getting actionable clinical insights and making data-driven decisions that improve the quality of patient care.

Tailored analytics to accurately detect SNVs and Indels in 42 genes associated with lung, colorectal, skin and brain cancers

Reduced turnaround time with a ready-to-sequence target-enriched library in just 1.5 days

CE-IVD marked SOPHiA DDM™ Platform web for intuitive reporting with unlimited and safe data storage

pink dots icon

Product Details

Accurately detect actionable variants

SOPHiA DDM™ Dx STS accuracy has been assessed through a multicenter performance evaluation study* showing:

  • High on-target rates and coverage uniformity
  • High-confidence calling of SNVs and Indels in 27 targeted genes
  • Clinical-grade analytical performance that can facilitate confident decision-making.

*Performance values have been calculated based on SNVs and Indels only, in 150 samples processed in 6 clinical centers on Illumina MiSeq™.

*5% quantile

Confidently generate comprehensive reports

SOPHiA DDM™ Dx STS includes direct access to SOPHiA DDM™ Platform web, a front-end application to upload and analyze genomic sample data and generate downloadable CE-IVD reports. It offers unlimited and unrestricted storage, while keeping patient data safe by applying the highest industrial standards of encryption in compliance with local data security policies.

workflow mobile image

Easily interpret clinically relevant variants

SOPHiA DDM™ Dx STS offers additional insights via SOPHiA DDM™ Platform core that allows users to visualize, interpret and report key biomarkers. Clinical Decision Support (CDS*) results are computed by the bioinformatics pipeline in a single workflow. CDS* reports include SNVs, Indels and gene amplification for the 42 targeted genes and can be tuned via intuitive cascading filters and prioritization options based on databases, in-house machine learning predictions, virtual panels or custom filters. Furthermore, a Microsatellite Instability (MSI) report is provided. Users also have access to SOPHiA GENETICS™ Community to share valuable knowledge with peers.

pink dots icon

Specifications

Parameters SOPHiA DDM™ Dx Solid Tumor Solution
Diseases Covered Lung, colorectal, skin and brain cancers
Genes 42 genes (AKT1, ALK, BRAF, CDK4, CDKN2A, CTNNB1, DDR2, DICER1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FOXL2, GNA11, GNAQ, GNAS, H3F3A, H3F3B, HIST1H3B, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MET, MYOD1, NRAS, PDGFRA, PIK3CA, PTPN11, RAC1, RAF1, RET, ROS1, SF3B1, SMAD4, TERT, TP53)
Sample Type FFPE tissue
DNA Input Amount 50 ng
Sequencer Compatibility Illumina MiSeq™
Library Preparation Time 1.5 days
Analysis Time From FASTQ < 4 hours
Detected Variants
  • SNVs
  • Indels
  • Gene amplification (CDS* only)
  • MSI, Microsatellite instability (CDS* only)
Product type Molecular diagnostic application (kit + analytics)
pink dots icon

Contact us

Please fill out the form below to get in touch

pink dots icon

Related products

SOPHiA DDM™ Solid Tumors Applications

Translate complex genomics data from solid tumors into valuable insights with our advanced applications.

SOPHiA DDM™ For Blood Cancers

CE-IVD Oncology Applications by SOPHiA GENETICS™

Transform raw next-generation sequencing (NGS) data into actionable insights with our CE-marked in vitro diagnostic (IVD) applications.

SOPHiA DDM™ For Solid Tumors

SOPHiA DDM™ Dx RNAtarget Oncology Solution (ROS)

Expect more from your RNA analyses with our diagnostic application providing reliable partner-agnostic detection of fusions in small lung cancer biopsy samples

SOPHiA DDM™ For Blood Cancers

SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution

Support accurate detection of HRD status in ovarian cancer patients with our diagnostic application leveraging low-pass WGS to measure genomic scarring.​

SOPHiA DDM™ For Solid Tumors

FFPE, formalin-fixed paraffin-embedded; Indels, insertions and deletions; MSI, Microsatellite instability; SNVs, single nucleotide variants
*CDS – For Clinical decision support use only – not intended as a primary diagnostic tool

';